We are live on ! Find out more
ATRC icon

AtriCure
ATRC

222 hedge funds and large institutions have $2.22B invested in AtriCure in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 88 increasing their positions, 74 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,767% more call options, than puts

Call options by funds: $730K | Put options by funds: $15K

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

19% more capital invested

Capital invested by funds: $1.86B → $2.22B (+$362M)

19% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 74

0.75% less ownership

Funds ownership: 96.05% → 95.3% (-0.75%)

1% less funds holding

Funds holding: 224 → 222 (-2)

4% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 24

Holders
222
Holders Change
-2
Holders Change %
-0.89%
% of All Funds
3.48%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
23
Increased
88
Reduced
74
Closed
24
Calls
$730K
Puts
$15K
Net Calls
+$715K
Net Calls Change
+$198K

Top Buyers

Rank Fund Capital Flow
1
Nuveen
Nuveen
North Carolina
+$13.2M
2
JP Morgan Chase
JP Morgan Chase
New York
+$12.4M
3
Millennium Management
Millennium Management
New York
+$8.77M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$8.47M
5
Man Group
Man Group
United Kingdom
+$5.76M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$9.99M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.8M
3
Marshall Wace
Marshall Wace
United Kingdom
-$7.69M
4
BNP Paribas Asset Management
BNP Paribas Asset Management
France
-$6.83M
5
PCM
Peregrine Capital Management
Minnesota
-$6.7M

ATRC Hedge Fund Activity: Q2 2023 in Review

222 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q2 2023, worth a combined $2.22B — up 19% from $1.86B a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ATRC and 23 opened new positions — a net loss of 1 holder — while 74 trimmed existing stakes and 88 added.

The largest buyer was Nuveen, adding an estimated $13.2M. The largest seller was Invesco, cutting an estimated $9.99M.

  • 222 institutional investors held AtriCure (ATRC) as of Q2 2023, down from 224 in Q1 2023.
  • Funds reported $2.22B of AtriCure stock for Q2 2023, up 19% quarter-over-quarter.
  • 23 funds opened new AtriCure positions in Q2 2023 and 24 closed out, a net change of -1 holder.
  • The largest AtriCure buyer in Q2 2023 was Nuveen, an estimated $13.2M added.
  • The largest AtriCure seller in Q2 2023 was Invesco, an estimated $9.99M sold.

Based on aggregated 13F filings for Q2 2023.